跳至主要内容
临床试验/NCT02800746
NCT02800746Unknown不适用

Preoperative Intravenous Iron Supplementation on Postoperative Hematocrit and Intraoperative Transfusion Amount in Prognathic Surgery

Konkuk University Medical Center0 个研究点目标入组 48 人开始时间: 2018年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
48
主要终点
Serum-Hematocrit

研究概览

简要总结

The objective of the present study is to determine the impact of preoperative IV-iron (ferric carboxy maltose) supplementation on postoperative hematocrit values and allogenic blood transfusion amount in patients undergoing elective prognathic surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with prognathism in undergoing elective prognathic surgery
  • Patients provided a written informed consent.
  • Patients with s-ferritin < 300 mg/dl (male) or 200 mg/dl (female)
  • Patients with preoperative Hematocrit > 39% (male) and > 36% 9female)serum hemoglobin >13 g/dL (male) and >12 g/dL (female)

排除标准

  • Patients with history of anaphylaxis, iron overload, active infection.
  • Patients with endocrine disease
  • Patients received or receiving intraoperative and preoperative blood salvaged, allogenic blood transfusion, anti-fibrinolytic agents or recombinant human erythropoietin, or undergoing acute normovolemic hemodilution.

研究组 & 干预措施

Experimental group

Experimental

Ferric carboxymaltose

干预措施: Ferric carboxymaltose (Drug)

Control Group

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Serum-Hematocrit

时间窗: Postoperative 2 hour

intergroup-difference immediately after surgery, %

次要结局

  • Serum-Ferritin level(Postoperative 2 hour)
  • Changes of serum-Ferritin level(Postoperative 2 hour)
  • Transfusion amount(Postoperative 2 hour)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tae-Yop Kim, MD PhD

Professor

Konkuk University Medical Center

相似试验